Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04189354
Other study ID # CHUB-PSY-COMBINTES 1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 12, 2019
Est. completion date June 23, 2021

Study information

Verified date July 2022
Source Brugmann University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Anxio-depressive disorders are characterized by a difficulty in regulating the negative or aversive emotions adequately. These dysfunctions have been linked to a deficit in prefrontal cortex activity. The latter has an inhibitory influence on limbic regions -especially the amygdala- involved in the generation of emotions. By this means, the prefrontal cortex intervenes in the control of the sympathetic and parasympathetic branches of the autonomic nervous system whp are responsible for the physiological components of the emotion, including the variations of the cardiac rhythm (HRV: heart rate variability). In emotionally demanding situations, the activity of the prefrontal cortex is generally associated with an increase in parasympathetic activity that is exerted by stimulation of the vagus nerve. In patients with anxio-depressive disorder, there is a decrease in the activity of the autonomic nervous system whose variability in heart rate is a recognized marker. Many studies show a beneficial impact of transcranial direct current stimulation (t-DCS) on anxio-depressive symptoms, particularly when a particular area is targeted: the dorso-lateral prefrontal cortex. The impacts of this intervention are multiple and aim in particular to modulate the activity of the autonomic nervous system to promote regulation. Biofeedback HRV is a technique that allows you to learn how to modulate your heart rate by means of respiratory control exercises. The patient receives an immediate feedback on the effectiveness of his learning (basic principle of bio-feedback). This intervention will allow to act on the parasympathetic activity and to promote a vagal tone adequate to the emotional regulation. Numerous studies have demonstrated the favorable impact of HRV biofeedback on the reduction of anxious and depressive symptoms. Since the vagus nerve seems to be a primary pathway in physiologically emotional regulation, and considering that vagal tone can be stimulated by both the activity of the prefrontal cortex and through respiratory control, it appears interesting to study the association of t-DCS with HRV biofeedback techniques. The first objective of this study is to show that HRV biofeedback training coupled with t-DCS is associated with a greater decrease in anxious symptomatology. The secondary objective of the study is to show that a coupling of these two techniques is associated with an increase of the variability of the cardiac rhythm as well as a more important decrease of the depressive symptomatology.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date June 23, 2021
Est. primary completion date June 23, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnose of anxio-depressive disorder - Good understanding of French - High anxiety level (STAI questionnaire score higher to 46) with reported difficulties to manage this anxiety. Exclusion Criteria: - Alcohol dependence (assessed by the AUDIT questionnaire) - Pregnancy - t-DCS contra indications : traumatic brain injury, epilepsy, known bipolar disease, electronic or metalic implant - Known cardiac arrhythmia or intake of beta-blockers

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Transcranial direct current stimulation (t-DCS) device
t-DCS is a brain electrostimulation technique that consists of applying a current of low intensity (between 1 and 2 mA) on the scalp via two electrodes, in order to modify the cerebral activity of the stimulated zones. The investigators use the Soterix Medical t-DCS devices of the mini-CT 1x1 type.

Locations

Country Name City State
Belgium CHU Brugmann Brussels

Sponsors (1)

Lead Sponsor Collaborator
Tatiana Besse-Hammer

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary State-trait anxiety inventory (STAI-Y) scores Questionnaire with 20 questions, each with 4 possible answers. Each answer corresponds to a score of 1 to 4, 1 indicating the lowest degree of anxiety and 4 the highest degree. Baseline (day 1)
Primary State-trait anxiety inventory (STAI-Y) scores Questionnaire with 20 questions, each with 4 possible answers. Each answer corresponds to a score of 1 to 4, 1 indicating the lowest degree of anxiety and 4 the highest degree. Day 8
Primary State-trait anxiety inventory (STAI-Y) scores Questionnaire with 20 questions, each with 4 possible answers. Each answer corresponds to a score of 1 to 4, 1 indicating the lowest degree of anxiety and 4 the highest degree. Day 29
Primary State-trait anxiety inventory (STAI-Y) scores Questionnaire with 20 questions, each with 4 possible answers. Each answer corresponds to a score of 1 to 4, 1 indicating the lowest degree of anxiety and 4 the highest degree. One time point between day 60 and day 90
Secondary Root mean square of successive differences (RMSSD) The Root Mean Square of the Successive Differences (RMSSD) is one of a few time-domain tools used to assess heart rate variability, the successive differences being neighboring RR intervals. Baseline (day 1)
Secondary Root mean square of successive differences (RMSSD) The Root Mean Square of the Successive Differences (RMSSD) is one of a few time-domain tools used to assess heart rate variability, the successive differences being neighboring RR intervals. Day 8
Secondary Root mean square of successive differences (RMSSD) The Root Mean Square of the Successive Differences (RMSSD) is one of a few time-domain tools used to assess heart rate variability, the successive differences being neighboring RR intervals. Day 29
Secondary Root mean square of successive differences (RMSSD) The Root Mean Square of the Successive Differences (RMSSD) is one of a few time-domain tools used to assess heart rate variability, the successive differences being neighboring RR intervals. One time point between day 60 and day 90
Secondary High frequency in spectral analysis Spectral analysis of the RR interval is an indirect, noninvasive measurement tool of heart rate variability. High-frequency RR signal (greater than 0.15 Hz) is associated with increased parasympathetic tone, and low-frequency RR signal (0.04-0.15 Hz) is associated with increased sympathetic tone. Baseline (day 1)
Secondary High frequency in spectral analysis Spectral analysis of the RR interval is an indirect, noninvasive measurement tool of heart rate variability. High-frequency RR signal (greater than 0.15 Hz) is associated with increased parasympathetic tone, and low-frequency RR signal (0.04-0.15 Hz) is associated with increased sympathetic tone. Day 8
Secondary High frequency in spectral analysis Spectral analysis of the RR interval is an indirect, noninvasive measurement tool of heart rate variability. High-frequency RR signal (greater than 0.15 Hz) is associated with increased parasympathetic tone, and low-frequency RR signal (0.04-0.15 Hz) is associated with increased sympathetic tone. Day 29
Secondary High frequency in spectral analysis Spectral analysis of the RR interval is an indirect, noninvasive measurement tool of heart rate variability. High-frequency RR signal (greater than 0.15 Hz) is associated with increased parasympathetic tone, and low-frequency RR signal (0.04-0.15 Hz) is associated with increased sympathetic tone. One time point between day 60 and day 90
Secondary Montgomery Asberg Depression Rating Scale (MADRS) The Montgomery-Åsberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. A total superior to 20/60 is generally considered abnormal. A level of 30 points is considered a definition of severe depression. Baseline (day 1)
Secondary Montgomery Asberg Depression Rating Scale (MADRS) The Montgomery-Åsberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. A total superior to 20/60 is generally considered abnormal. A level of 30 points is considered a definition of severe depression. Day 8
Secondary Montgomery Asberg Depression Rating Scale (MADRS) The Montgomery-Åsberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. A total superior to 20/60 is generally considered abnormal. A level of 30 points is considered a definition of severe depression. Day 29
Secondary Montgomery Asberg Depression Rating Scale (MADRS) The Montgomery-Åsberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. A total superior to 20/60 is generally considered abnormal. A level of 30 points is considered a definition of severe depression. One time point between day 60 and day 90
See also
  Status Clinical Trial Phase
Recruiting NCT06065787 - NeuroGlove Anxiety and Depression Study N/A
Completed NCT03981406 - Palliative Care and Quality of Life in Idiopathic Pulmonary Fibrosis N/A
Not yet recruiting NCT05911412 - Development of the Neuroimaging Biomarker-based Prediction Model of Anxiety-related Disorders: Effect of Mindfulness-based Cognitive Therapy Using Neuroscience on the Brain N/A
Not yet recruiting NCT05860257 - Transforming Adolescent Mental Health Through Accessible, Scalable, Technology-supported Small-group Instruction N/A
Recruiting NCT05390034 - Improving Emotion Regulation Flexibility: Testing the Efficacy of an Emotion Regulation Program in College Students N/A
Completed NCT04307563 - Effects of Mindfulness Training on Burnout and Mood in Hospital Employees N/A
Recruiting NCT06190184 - Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Conditions N/A
Enrolling by invitation NCT05529381 - Anxiety and Depressive Symptoms in Placenta Previa / Accreta
Active, not recruiting NCT03090867 - Participation of Relative or Surrogate in the Patient's Care in Reanimation N/A
Completed NCT05150574 - HRV and Coaching Preparation Phase Study Phase 1
Completed NCT03889301 - ¡Yo no Estoy Loc@! Improving Treatment Engagement for Latinos Using an E-E Video N/A
Completed NCT04498442 - A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls N/A
Not yet recruiting NCT03190291 - A Stepped-Care Telehealth Approach To Treat Distress In Rural Cancer Survivors N/A
Recruiting NCT04406181 - Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic N/A
Completed NCT05871580 - Effect to the Photobiomodulation in the Burning Mouth Syndrome N/A
Completed NCT04299256 - Benson Relaxation Technique Combined With Music Therapy for Fatigue, Anxiety, and Depression in Hemodialysis Patients N/A
Recruiting NCT05570812 - Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV Phase 2
Completed NCT04572659 - Psychosocial Intervention in Assisted Reproduction Treatments N/A
Not yet recruiting NCT06035731 - Evaluation of the Medical Service by Socio-aesthetics in Oncology N/A
Recruiting NCT04211376 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Anxiety